UK Neuroscience Research Priority Area: Providing broad based research support for the UK Neuroscience community

The Neuroscience Research Priority Area (NRPA) supports a "collaborative matrix," bringing together diverse groups of investigators, trainees, and research groups from more than 8 University of Kentucky colleges. The NRPA builds upon and leverages existing strengths and relationships; providing infrastructure and support to promote research collaborations and raise internal and external recognition of the depth of neuroscience-related research at the university with the goals of growing extramural support, increasing academic productivity, enhancing recruitment of faculty and trainees, and providing new knowledge to address the needs of the citizens of the Commonwealth and beyond. 


  Neuroscience Extramural Award Growth: 2015-2021 (CAGR 22%)
Neuroscience Extramural Award Growth: 2015-2021 (Compund Annual Growth Rate 22%)


Join the NRPA!

We welcome new/experienced research collaborators to join the Neuroscience RPA team. 

The Latest in Neuroscience at UK

Larry Goldstein, M.D., chair of the University of Kentucky Department of Neurology. Photo by Shaun Ring.

UK’s Goldstein leads new scientific statement by the American Heart Association

Larry Goldstein, M.D., chair of the University of Kentucky Department of Neurology, chaired the writing group for a newly published scientific statement. The statement was published in the American Heart Association/American Stroke Association's (AHA/ASA) peer reviewed journal Arteriosclerosis, Thrombosis, and Vascular Biology

Tritia Yamasaki, Ph.D., assistant professor in neurology in the College of Medicine, is researching metabolomics and Parkinson’s disease.

NIH awards $10.6 million for central nervous system metabolism research center at UK

UK has been awarded a prestigious Centers of Biomedical Research Excellence (COBRE) grant to study central nervous system metabolism from the National Institute of General Medical Sciences (NIGMS), part of the National Institutes of Health. The $10.6 million, five-year grant will fund UK’s Center of Research in Central Nervous System Metabolism (CNS-Met). 

Beiberich Lab

UK researchers 1st to show multiple sclerosis drug can be used as Alzheimer’s therapy


A team of researchers at the University of Kentucky has found that a drug used to treat multiple sclerosis (MS) is potentially effective as a therapy for Alzheimer’s disease.


Neuroscience News

See news on Neuroscience-based research at UK. 




Click below to see recent research from the Neuroscience Research Priority Area in Scholars@UK.